In a previous study, we have identified endonexin II (E-II) on human liver plasma membranes as a specific, Ca2+-dependent, small hepatitis B surface antigen (HBsAg)-binding protein. In this article, we describe the spontaneous development of anti-HBs antibodies in rabbits immunized with native or recombinant human liver E-II and in chickens immunized with the F(ab')2 fragment of rabbit anti-human liver E-II immunoglobulin G. Anti-HBs activity was not observed in rabbits immunized with rat liver E-II. Cross-reactivity of anti-E-II antibodies to HBsAg epitopes was excluded, since anti-HBs and anti-E-II activities can be separated by E-II affinity chromatography. The existence of an anti-idiotypic antibody is further demonstrated by competitive binding of human liver E-II and this antibody (Ab2) to small HBsAg, suggesting that Ab2 mimics a specific E-II epitope that interacts with small HBsAg. In addition, it was demonstrated that anti-HBs antibodies developed in rabbits after immunization with intact human liver E-II or in chickens after immunization with F(ab')2 fragments of rabbit anti-human liver E-II immunoglobulin G recognize the same epitopes on small HBsAg. These findings strongly indicate that human liver E-II is a very specific small HBsAg-binding protein and support the assumption that human liver E-II is the hepatitis B virus receptor protein.
Hepatitis B is a worldwide public health problem with significant morbidity and mortality rates (5) . Although much information on the molecular biology of hepatitis B virus (HBV) has been gained in the last decade, so far little is known about the mechanism of attachment and penetration of HBV into the hepatocyte, the natural host cell of HBV. However, the viral envelope proteins (large, middle, and small hepatitis B surface antigens [HBsAg] ) are considered crucial molecules in recognizing a possible receptor on plasma membranes of human hepatocytes (6, 15) . All three molecular forms of HBV envelope proteins have the small S sequences (226 amino acids) (small HBsAg) in common but differ in their aminoterminal extensions. Middle HBsAg consists of the S sequence and a pre-S2 (55-amino-acid) sequence, while large HBsAg contains S, pre-S2, and pre-Sl (108-to 119-amino-acid) sequences. On the basis of studies by others, it has been reported that the pre-Sl region (amino acid residues 21 to 47) of large HBsAg showed an attachment site for plasma membranes (4, 18, 19, 21, 23) . However, a human liver protein that specifically binds to pre-Si peptide has not yet been identified (4, 21) . In addition, it has also been found that middle HBsAg binds specifically to monomeric or polymerized human serum albumin via its pre-S2 region (3, 12, 16, 27 ) and polymerized human serum albumin binds to hepatocytes, although this binding is not species specific. In a previous study, we demonstrated that radiolabeled small HBsAg specifically binds to intact adult human hepatocytes (14) , and recently we have identified human liver endonexin II (E-II), present on human plasma membranes, as a specific binding protein of small HBsAg (8) . In this article, we report the spontaneous development of anti-HBs (anti-idiotypic) antibodies in rabbits immunized with human liver E-II and in chickens immunized with the F(ab')2 fragment of rabbit anti-human liver E-II immunoglobulin G (IgG), suggesting the existence of an intimate interaction between human liver E-II and the small envelope protein of HBV. and allowed to stand overnight at 4°C. Subsequently, the mixture was incubated with protein A-Sepharose for 3 h at 4°C. and of rabbits after immunization with human liver E-II (0, native; *, recombinant) or rat liver E-II (A), as determined by ELISA.
MATERIALS AND METHODS
PBS-3% gelatin (Merck, Darmstadt, Germany) to block nonspecific binding sites, and washed with PBS-0.05% Tween 20. Wells were then incubated with binding mixtures (radiolabeled 
RESULTS
ELISA of rabbit antiserum. Since immunization of rabbits with a specific ligand could lead to development of antiidiotypic antibodies, reacting to its specific receptor (13) , and to investigate whether this is also the case with rabbits immunized with human liver E-II, a specific hepatitis B virus envelope-binding protein (8) , rabbits immunized with human liver E-TI were bled at intervals and examined by ELISA to determine the possible presence of anti-HBs activity (Fig. 1) . As shown in Fig. 1 showed comparable anti-HBs activities. This activity was specific, since preimmune serum did not react with small HBsAg and anti-HBs activity, as determined by ELISA, could be eliminated by preincubation of the antiserum with excess small HBsAg (Fig. 2) . In contrast, rabbits immunized with rat liver E-TI, which does not have HBsAg-binding properties despite 90% sequence homology compared with human liver E-II (8, 20) , did not develop anti-HBs antibodies (Fig. 1) .
Separation of idiotypic and anti-idiotypic antibodies. To exclude the possibility of cross-reactivity of anti-E-IT to HBsAg epitopes, the anti-HBs and anti-E-II activities present in rabbit serum were separated by affinity chromatography using recombinant E-Il coupled to CNBr-activated Sepharose. Flowthrough fractions (1 to 12) (Fig. 3) as well as eluted fractions (13 to 18) (Fig. 3 ) from the affinity column were collected and examined for their reactivities with small HBsAg and E-II (ELISA). As demonstrated in Fig. 3 , the anti-HBs activity was found predominantly in the flowthrough fractions (1 to 6), while anti-E-TI reactivity was found exclusively in the eluted fractions (14 to 17), indicating that the anti-HBs reactivity in rabbit anti-E-TI antiserum is not due to a cross-reactivity of anti-E-II antibodies to small HBsAg epitopes.
Immuno-dot blot analysis. To verify the above-mentioned results as determined by ELISA, small HBsAg and E-II were spotted on nitrocellulose filters and incubated with different antisera. Figure 4 shows that rabbit antiserum is reactive to   FIG. 3 . Separation of antibodies, reacting with smal human liver E-II, by recombinant human liver E-II col tography. As determined by ELISA, anti-HBs reactivity ( predominantly in the flowthrough fractions (1 to 6), w reactivity (-) was found exclusively in the eluted fractic both human liver E-II and small HBsAg while the flowthrough fraction of protein A and E-II column chromatography-purified anti-HBs antibodies is reactive only to small HBsAg.
Immunoprecipitation of radiolabeled small HBsAg. To investigate whether antibodies, separated as mentioned above, were also reactive to antigens in solution, experiments were performed with radiolabeled human liver E-II and radiolabeled small HBsAg. As shown in Fig. 5 , both radiolabeled proteins could be precipitated by sera of rabbits immunized with human liver E-TI, while preimmune sera were not able to precipitate these radiolabeled proteins. The precipitation of radiolabeled proteins was reduced by the addition of unlabeled excess of the respective proteins.
Competitive binding experiments. To examine whether the anti-HBs antibody, found in rabbits immunized with human liver E-IT, is an anti-idiotypic antibody (Ab2) that reacts with a specific epitope(s) on small HBsAg that binds to human liver E-II, competitive binding studies were performed with Ab2 immobilized on high-bond ELISA dishes. As shown in Fig. 6 , human liver E-1I successfully competes with the anti-HBs antibody for binding to small HBsAg in the presence of Ca2+ and Mg2+. It is, therefore, concluded that the anti-HBs antibody mimics a region of E-II that interacts with small HBsAg.
Immunization of chickens with the anti-E-II F(ab')2 fragment. A more direct method to investigate whether idiotypic antibodies are able to induce anti-idiotypic antibody formation is the immunization of animals with a purified F(ab')2 frag- ment of the idiotypic antibodies. To investigate whether anti-E-TI antibodies were able to induce anti-HBs antibodies, chickens were immunized with a purified anti-E-I1 F(ab')2 fragment. Reactivity was examined by ELISA of the isolated 7S Ig from egg yolk. As shown in Fig. 7 , a high titer of anti-HBs antibodies (and anti-rabbit IgG response) was indeed found after immunization of chickens with the rabbit anti-E-TI F(ab')2 fragment.
Competitive binding of anti-idiotypic antibodies to HBsAg. To investigate whether the anti-HBs antibodies, induced in rabbits by immunization with intact E-IT (Ab2/E-IT), recognize the same (or identical) epitopes on small HBsAg as antibodies induced in chickens by immunization with the F(ab')2 fragment [Ab2/F(ab')2j, a competitive binding study was performed. For this purpose, HBsAg column chromatography affinity-purified Ab2/E-II from rabbits immunized with human antibodies found in chickens immunized with the anti-E-II F(ab')2 fragment recognize identical regions on small HBsAg.
DISCUSSION
Despite the tremendous efforts of the past years, the exact mechanism of viral entry of HBV into its target cells is still unknown. However, the restricted host and tissue tropism of HBV infection suggests the existence of specific receptor molecules. Although the importance of pre-Sl and pre-S2 sequences for attachment and penetration of HBV into human hepatocytes may be significant (7), circumstantial evidence indicates that the role of small HBsAg in attachment of HBV to target cells cannot be ruled out. (i) It has been demonstrated that radiolabeled small HBsAg specifically binds to intact normal human hepatocytes and to a human hepatoblastoma cell line (HepG2) (11, 14) . (ii) Vaccination with recombinant or serum-derived HBsAg is based on eliciting protective anti-small HBsAg antibodies (1, 17) , a conclusion which is further confirmed by the appearance of a vaccine escape mutant with an altered "a" epitope within the S region (2, 25) . (iii) Monoclonal antibodies to restricted epitopes of small HBsAg have been shown to be virus neutralizing (9, 26) , and monoclonal antibodies to small HBsAg show an inhibitory effect on the binding of viral particles to HepG2 cells more efficiently than monoclonal antibodies directed to pre-Sl sequences (22) . Recently, we have identified human liver E-TI, present on hepatocyte membranes, as a specific small HBsAgbinding protein. In addition, despite the fact that rat liver E-TI shows a sequence homology of 90% to human liver E-II (20), rat liver E-TI does not exhibit small HBsAg-binding properties (8) . In this article, we report the finding of anti-HBs antibodies developed in rabbits immunized with native human liver E-TI or human liver E-TI isolated from recombinant yeast cells (to be described elsewhere). This anti-HBs antibody was not found in rabbits immunized with rat liver E-TI. The presence of anti-HBs activity may suggest three possibilities. The first is that the human liver E-IT, used as an antigen, might be contaminated with HBsAg. However, the liver tissue used for this purpose was found to be HBsAg negative, and a retrospective investigation revealed no contamination of the original batch of E-TI with HBsAg. Moreover, the antibody raised in that case should react to various epitopes of HBsAg. This seems unlikely, since this antibody contains no anti-pre-Sl activity nor has an inhibitory effect on the interaction between small HBsAg and several murine monoclonal antibodies (data not shown). Furthermore, rabbits immunized with human liver E-IT from recombinant yeast cells were found to induce anti-HBs antibodies as well. The second possibility is that this antibody might react with a common epitope shared by human liver E-TI and HBsAg (cross-reactivity). In order to examine this hypothesis, the anti-HBs and anti-E-TI antibodies, present in rabbit immune serum, were affinity purified by using recombinant E-TI coupled to CNBr-activated Sepharose. As demonstrated in Fig. 3 , the anti-HBs activity can be separated from antibody reactive to E-IT, indicating that the anti-HBs activity is not due to a cross-reactivity. Finally, the anti-HBs antibody might be an anti-idiotypic antibody (Ab2). The immunization of chickens with the anti-E-TI F(ab')2 fragment and the subsequent development of anti-HBs antibodies, which can be selectively purified by HBsAg column chromatography, prove that it is indeed a specific anti-idiotypic response, containing antibodies that react with a site(s) on small HBsAg that binds to human liver E-IT. In this case, human liver E-IT should be able to compete with the anti-HBs antibodies, isolated from the sera of rabbits immunized with E-TI or from egg yolk of chickens immunized with the F(ab')2 fragment of rabbit anti-E-TI IgG, for the E-TI-binding site on small HBsAg. Indeed, human liver E-TI shows a competitive effect for binding to small HBsAg with these anti-HBs antibodies, indicating that these antibodies mimic a region of E-TI that interacts with small HBsAg. From experimental animals immunized with human liver E-TI such anti-idiotypic antibodies can be induced only if human liver E-TT and small HBsAg indeed have intimate binding properties.
These findings, therefore, strongly indicate an intimate interaction, resembling a receptor-ligand relationship between human liver E-IT and small HBsAg, and support the assumption that human liver E-IT is an HBV receptor protein. However , further studies to demonstrate that this protein is involved in the initial steps of viral entry into liver cells are necessary.
